Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Cerebrospinal fluid biomarkers of malignancies located in the central nervous system.

Verheul C, Kleijn A, Lamfers MLM.

Handb Clin Neurol. 2017;146:139-169. doi: 10.1016/B978-0-12-804279-3.00010-1.

PMID:
29110768
2.

The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8+T Cell Anti-tumor Activity.

Kleijn A, van den Bossche W, Haefner ES, Belcaid Z, Burghoorn-Maas C, Kloezeman JJ, Pas SD, Leenstra S, Debets R, de Vrij J, Dirven CMF, Lamfers MLM.

Mol Ther Oncolytics. 2017 Mar 1;5:11-19. doi: 10.1016/j.omto.2017.02.002. eCollection 2017 Jun 16.

3.

TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.

Venkatesan S, Hoogstraat M, Caljouw E, Pierson T, Spoor JK, Zeneyedpour L, Dubbink HJ, Dekker LJ, van der Kaaij M, Kloezeman J, Berghauser Pont LM, Besselink NJ, Luider TM, Joore J, Martens JW, Lamfers ML, Sleijfer S, Leenstra S.

Oncotarget. 2016 Sep 6;7(36):58435-58444. doi: 10.18632/oncotarget.11205.

4.

Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells.

Balvers RK, Dirven CM, Leenstra S, Lamfers ML.

Curr Cancer Drug Targets. 2017;17(3):255-266. doi: 10.2174/1568009616666160813191809. Review.

PMID:
27528360
5.

A Systematic Comparison Identifies an ATP-Based Viability Assay as Most Suitable Read-Out for Drug Screening in Glioma Stem-Like Cells.

Kleijn A, Kloezeman JJ, Balvers RK, van der Kaaij M, Dirven CM, Leenstra S, Lamfers ML.

Stem Cells Int. 2016;2016:5623235. doi: 10.1155/2016/5623235. Epub 2016 May 5.

6.

Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.

Venkatesan S, Lamfers ML, Dirven CM, Leenstra S.

CNS Oncol. 2016;5(2):77-90. doi: 10.2217/cns-2015-0005. Epub 2016 Mar 17. Review. Erratum in: CNS Oncol. 2016 Jul;5(3):188.

PMID:
26986934
7.

DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors.

Mazor T, Pankov A, Johnson BE, Hong C, Hamilton EG, Bell RJA, Smirnov IV, Reis GF, Phillips JJ, Barnes MJ, Idbaih A, Alentorn A, Kloezeman JJ, Lamfers MLM, Bollen AW, Taylor BS, Molinaro AM, Olshen AB, Chang SM, Song JS, Costello JF.

Cancer Cell. 2015 Sep 14;28(3):307-317. doi: 10.1016/j.ccell.2015.07.012.

8.

In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells.

Berghauser Pont LM, Balvers RK, Kloezeman JJ, Nowicki MO, van den Bossche W, Kremer A, Wakimoto H, van den Hoogen BG, Leenstra S, Dirven CM, Chiocca EA, Lawler SE, Lamfers ML.

Gene Ther. 2015 Dec;22(12):947-59. doi: 10.1038/gt.2015.72. Epub 2015 Jul 21.

PMID:
26196249
9.

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.

Berghauser Pont LM, Kleijn A, Kloezeman JJ, van den Bossche W, Kaufmann JK, de Vrij J, Leenstra S, Dirven CM, Lamfers ML.

PLoS One. 2015 May 18;10(5):e0127058. doi: 10.1371/journal.pone.0127058. eCollection 2015.

10.

The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity.

Kleijn A, Kloezeman J, Treffers-Westerlaken E, Fulci G, Leenstra S, Dirven C, Debets R, Lamfers M.

Oncoimmunology. 2014 Dec 13;3(9):e955697. eCollection 2014 Oct.

11.

ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.

Balvers RK, Lamfers ML, Kloezeman JJ, Kleijn A, Berghauser Pont LM, Dirven CM, Leenstra S.

J Transl Med. 2015 Feb 26;13:74. doi: 10.1186/s12967-015-0427-y.

12.

Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells.

de Vrij J, Maas SL, Kwappenberg KM, Schnoor R, Kleijn A, Dekker L, Luider TM, de Witte LD, Litjens M, van Strien ME, Hol EM, Kroonen J, Robe PA, Lamfers ML, Schilham MW, Broekman ML.

Int J Cancer. 2015 Oct 1;137(7):1630-42. doi: 10.1002/ijc.29521. Epub 2015 Apr 7.

13.

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.

van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, Malmström A, Hallbeck M, Heimans JJ, Kloezeman JJ, Stenmark-Askmalm M, Lamfers ML, Saito N, Aburatani H, Mukasa A, Berger MS, Söderkvist P, Taylor BS, Molinaro AM, Wesseling P, Reijneveld JC, Chang SM, Ylstra B, Costello JF.

Acta Neuropathol. 2015 Apr;129(4):597-607. doi: 10.1007/s00401-015-1403-6. Epub 2015 Feb 28.

14.

Establishing the Lysine-rich Protein CEST Reporter Gene as a CEST MR Imaging Detector for Oncolytic Virotherapy.

Farrar CT, Buhrman JS, Liu G, Kleijn A, Lamfers ML, McMahon MT, Gilad AA, Fulci G.

Radiology. 2015 Jun;275(3):746-54. doi: 10.1148/radiol.14140251. Epub 2015 Feb 13.

15.

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells.

Berghauser Pont LM, Spoor JK, Venkatesan S, Swagemakers S, Kloezeman JJ, Dirven CM, van der Spek PJ, Lamfers ML, Leenstra S.

Genes Cancer. 2014 Nov;5(11-12):445-59.

16.

Complement activation in Glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue.

Bouwens TA, Trouw LA, Veerhuis R, Dirven CM, Lamfers ML, Al-Khawaja H.

J Neuroimmunol. 2015 Jan 15;278:271-6. doi: 10.1016/j.jneuroim.2014.11.016. Epub 2014 Nov 18.

17.

DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells.

Pont LM, Naipal K, Kloezeman JJ, Venkatesan S, van den Bent M, van Gent DC, Dirven CM, Kanaar R, Lamfers ML, Leenstra S.

Cancer Lett. 2015 Jan 28;356(2 Pt B):525-35. doi: 10.1016/j.canlet.2014.09.049. Epub 2014 Oct 8.

PMID:
25305451
18.

Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.

Belcaid Z, Lamfers ML, van Beusechem VW, Hoeben RC.

Hum Gene Ther. 2014 Oct;25(10):875-84. doi: 10.1089/hum.2014.092. Epub 2014 Sep 17. Review.

19.

Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.

Balvers RK, Belcaid Z, van den Hengel SK, Kloezeman J, de Vrij J, Wakimoto H, Hoeben RC, Debets R, Leenstra S, Dirven C, Lamfers ML.

Viruses. 2014 Aug 12;6(8):3080-96. doi: 10.3390/v6083080.

20.

The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.

Kleijn A, Kloezeman J, Treffers-Westerlaken E, Fulci G, Leenstra S, Dirven C, Debets R, Lamfers M.

PLoS One. 2014 May 27;9(5):e97495. doi: 10.1371/journal.pone.0097495. eCollection 2014.

21.

Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.

Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM, Gomez-Manzano C, Fueyo J.

PLoS One. 2014 May 14;9(5):e97407. doi: 10.1371/journal.pone.0097407. eCollection 2014.

22.

Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules.

Balvers RK, Kleijn A, Kloezeman JJ, French PJ, Kremer A, van den Bent MJ, Dirven CM, Leenstra S, Lamfers ML.

Neuro Oncol. 2013 Dec;15(12):1684-95. doi: 10.1093/neuonc/not116. Epub 2013 Sep 17.

23.

Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures.

van den Hengel SK, Balvers RK, Dautzenberg IJ, van den Wollenberg DJ, Kloezeman JJ, Lamfers ML, Sillivis-Smit PA, Hoeben RC.

Cancer Gene Ther. 2013 Sep;20(9):507-13. doi: 10.1038/cgt.2013.47. Epub 2013 Aug 2.

PMID:
23907517
24.

Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.

de Jonge J, Berghauser Pont LM, Idema S, Kloezeman JJ, Noske D, Dirven CM, Lamfers ML.

J Gene Med. 2013 Mar-Apr;15(3-4):134-41. doi: 10.1002/jgm.2703.

PMID:
23606319
25.

Quantification of nanosized extracellular membrane vesicles with scanning ion occlusion sensing.

de Vrij J, Maas SL, van Nispen M, Sena-Esteves M, Limpens RW, Koster AJ, Leenstra S, Lamfers ML, Broekman ML.

Nanomedicine (Lond). 2013 Sep;8(9):1443-58. doi: 10.2217/nnm.12.173. Epub 2013 Feb 5.

PMID:
23384702
26.

[Exosomes and cancer].

de Vrij J, Maas SL, Hegmans JP, Lamfers ML, Dirven CM, Broekman ML.

Ned Tijdschr Geneeskd. 2011;155(51):A3677. Review. Dutch.

PMID:
22200143
27.

Anatomical differences determine distribution of adenovirus after convection-enhanced delivery to the rat brain.

Idema S, Caretti V, Lamfers ML, van Beusechem VW, Noske DP, Vandertop WP, Dirven CM.

PLoS One. 2011;6(10):e24396. doi: 10.1371/journal.pone.0024396. Epub 2011 Oct 13.

28.

Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging.

Kleijn A, Chen JW, Buhrman JS, Wojtkiewicz GR, Iwamoto Y, Lamfers ML, Stemmer-Rachamimov AO, Rabkin SD, Weissleder R, Martuza RL, Fulci G.

Clin Cancer Res. 2011 Jul 1;17(13):4484-93. doi: 10.1158/1078-0432.CCR-11-0575. Epub 2011 May 10.

29.

Truncating the i-leader open reading frame enhances release of human adenovirus type 5 in glioma cells.

van den Hengel SK, de Vrij J, Uil TG, Lamfers ML, Sillevis Smitt PA, Hoeben RC.

Virol J. 2011 Apr 11;8:162. doi: 10.1186/1743-422X-8-162.

30.

IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo.

Bralten LB, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M, Leenstra S, de Jonge H, Kros JM, Jansen EE, Struys EA, Jakobs C, Salomons GS, Diks SH, Peppelenbosch M, Kremer A, Hoogenraad CC, Smitt PA, French PJ.

Ann Neurol. 2011 Mar;69(3):455-63. doi: 10.1002/ana.22390.

PMID:
21446021
31.

Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma.

van Putten EH, Dirven CM, van den Bent MJ, Lamfers ML.

Future Oncol. 2010 Nov;6(11):1691-710. doi: 10.2217/fon.10.134. Review.

PMID:
21142657
32.

Objective determination of the oncolytic potency of conditionally-replicating adenoviruses using mathematical modeling.

Idema S, Dirven CM, van Beusechem VW, Carette JE, Planqué R, Noske DP, Lamfers ML, Vandertop WP.

J Gene Med. 2010 Jul;12(7):564-71. doi: 10.1002/jgm.1468.

PMID:
20603863
33.

Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma.

Verheije MH, Lamfers ML, Würdinger T, Grinwis GC, Gerritsen WR, van Beusechem VW, Rottier PJ.

J Virol. 2009 Aug;83(15):7507-16. doi: 10.1128/JVI.00495-09. Epub 2009 May 13.

34.

Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection.

Lamfers M, Idema S, van Milligen F, Schouten T, van der Valk P, Vandertop P, Dirven C, Noske D.

Cancer Lett. 2009 Feb 8;274(1):78-87. doi: 10.1016/j.canlet.2008.08.035. Epub 2008 Oct 7.

PMID:
18842332
35.

Characterization of infectivity of knob-modified adenoviral vectors in glioma.

Paul CP, Everts M, Glasgow JN, Dent P, Fisher PB, Ulasov IV, Lesniak MS, Stoff-Khalili MA, Roth JC, Preuss MA, Dirven CM, Lamfers ML, Siegal GP, Zhu ZB, Curiel DT.

Cancer Biol Ther. 2008 May;7(5):786-93.

PMID:
18756624
36.

Evaluation of adenoviral oncolytic effect on glioma spheroids by 18F-DG positron-emission tomography.

Idema S, Geldof AA, Dirven CM, van der Jagt M, Gerritsen WR, Vandertop WP, Lamfers ML.

Oncol Res. 2007;16(10):471-7.

PMID:
18196871
37.

Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.

Lamfers ML, Idema S, Bosscher L, Heukelom S, Moeniralm S, van der Meulen-Muileman IH, Overmeer RM, van der Valk P, van Beusechem VW, Gerritsen WR, Vandertop WP, Dirven CM.

Clin Cancer Res. 2007 Dec 15;13(24):7451-8.

38.

AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy.

Idema S, Lamfers ML, van Beusechem VW, Noske DP, Heukelom S, Moeniralm S, Gerritsen WR, Vandertop WP, Dirven CM.

J Gene Med. 2007 Dec;9(12):1046-56.

PMID:
17966130
39.

Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models.

Van Houdt WJ, Wu H, Glasgow JN, Lamfers ML, Dirven CM, Gillespie GY, Curiel DT, Haviv YS.

Neuro Oncol. 2007 Jul;9(3):280-90. Epub 2007 May 23.

40.

Evolving gene therapy approaches for osteosarcoma using viral vectors: review.

Witlox MA, Lamfers ML, Wuisman PI, Curiel DT, Siegal GP.

Bone. 2007 Apr;40(4):797-812. Epub 2006 Dec 26. Review.

41.

Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.

Lamfers ML, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B, Moeniralm S, Saeki Y, Carette JE, Weissleder R, Vandertop WP, van Beusechem VW, Dirven CM, Chiocca EA.

Mol Ther. 2006 Dec;14(6):779-88. Epub 2006 Sep 22.

42.

The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.

Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lamfers ML, Rein D, Lesniak MS, Siegal GP, Dirven CM, Curiel DT, Zhu ZB.

J Neurosurg. 2006 Apr;104(4):583-92.

PMID:
16619663
43.

Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.

Lamfers ML, Gianni D, Tung CH, Idema S, Schagen FH, Carette JE, Quax PH, Van Beusechem VW, Vandertop WP, Dirven CM, Chiocca EA, Gerritsen WR.

Cancer Res. 2005 Oct 15;65(20):9398-405.

44.

Oncolytic virotherapy of meningiomas in vitro with replication-competent adenovirus.

Grill J, Lamfers ML, van Beusechem VW, van der Valk P, Huisman A, Sminia P, Alemany R, Curiel DT, Vandertop WP, Gerritsen WR, Dirven CM.

Neurosurgery. 2005;56(1):146-53; discussion 153-4.

PMID:
15617597
45.

Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology.

Chiocca EA, Broaddus WC, Gillies GT, Visted T, Lamfers ML.

J Neurooncol. 2004 Aug-Sep;69(1-3):101-17. Review.

PMID:
15527083
46.

Multicellular tumor spheroids in gene therapy and oncolytic virus therapy.

Lamfers ML, Hemminki A.

Curr Opin Mol Ther. 2004 Aug;6(4):403-11. Review.

PMID:
15468599
47.

Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells.

Sachs MD, Ramamurthy M, Poel Hv, Wickham TJ, Lamfers M, Gerritsen W, Chowdhury W, Li Y, Schoenberg MP, Rodriguez R.

Cancer Gene Ther. 2004 Jul;11(7):477-86.

PMID:
15118762
48.

[Conditionally replicative adenoviruses: a second wind for cancer gene therapy].

Grill J, Geoerger B, Lamfers M, Dirven C, Van Beusechem V, Gerritsen W, Vassal G.

Bull Cancer. 2003 Dec;90(12):1039-48. French.

49.

Adenoviral delivery of a constitutively active retinoblastoma mutant inhibits neointima formation in a human explant model for vein graft disease.

Lamfers ML, Aalders MC, Grimbergen JM, de Vries MR, Kockx MM, van Hinsbergh VW, Quax PH.

Vascul Pharmacol. 2002 Dec;39(6):293-301.

PMID:
14567067
50.

Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors.

van Beusechem VW, Mastenbroek DC, van den Doel PB, Lamfers ML, Grill J, Würdinger T, Haisma HJ, Pinedo HM, Gerritsen WR.

Gene Ther. 2003 Nov;10(23):1982-91.

PMID:
14528322

Supplemental Content

Loading ...
Support Center